Abivax S.A.
ABVX
Rank in Stocks
#2358
Abivax S.A. is a Paris-based pharmaceutical firm, established in 2013,... Abivax S.A. is a Paris-based pharmaceutical firm, established in 2013, dedicated to identifying and refining treatments for various serious conditions, including inflammatory and infectious diseases, as well as cancer. Its primary drug candidate, ABX464, is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's disease, and COVID-19, and is in Phase IIa trials for rheumatoid arthritis. This compound has also successfully completed a Phase IIa study focused on achieving viral remission in HIV patients. Additionally, the company is advancing ABX 196, an immune-enhancing agent, through Phase 1/2 clinical trials for hepatocellular cancer. Beyond these main programs, Abivax is also engaged in research initiatives targeting Dengue fever, influenza, and the respiratory syncytial virus. The company holds significant licensing agreements with esteemed institutions such as the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie.
Share Price
$95.29
Last synced: 2026-10-21
Market Cap
$8.32B
Change (1 day)
-3.50%
Change (1 year)
7.83%
Country
FR
Trade Abivax S.A. (ABVX)
Category
Healthcare
Stock price history for Abivax S.A. (ABVX)
Highest end of day price: $94.93 on 2026-10-01
Lowest end of day price: $23.10 on 2015-06-01
Lowest end of day price: $23.10 on 2015-06-01
Stock price history of Abivax S.A. from 2015 to 2026
Annual Stock Price Performance
| Year | Performance |
|---|---|
| 2026 (TTM) | -5.95% |
| 2025 | 1,503.20% |
| 2024 | -26.43% |
| 2023 | 60.28% |
| 2022 | -77.75% |
| 2021 | -2.30% |
| 2020 | 54.91% |
| 2019 | 56.94% |
| 2018 | 22.67% |
| 2017 | 47.19% |
| 2016 | -57.07% |
| 2015 | 0.00% |
Stock price for similar companies or competitors
| Company | Stock price | Change 1y% | Country |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.79 | -3.81% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
